Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen Inc. (NASDAQ:AMGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Amgen Inc. (NASDAQ:AMGN) reported ...

Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter.

AMGN posts strong Q2 results as Repatha, Evenity, Blincyto and rare disease drugs power broad-based volume gains.

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

The stock slipped 3.5% postmarket after the chip maker reported adjusted earnings per share in line with estimates.

Amgen reported total revenue of $9.2 billion, topping the consensus of $8.9 billion, and non-GAAP earnings of $6.02 per share ...

Amgen (NASDAQ:AMGN) surpasses Q2 earnings and revenue expectations with a 9.4% revenue growth. Read more here.

The stock's fall snapped a two-day winning streak.

Explore Amgen's Q2 2025 earnings insights, showcasing 9% revenue growth, robust product performance, and innovation in obesity, rare disease, and ...

In a report released today, from Oppenheimer maintained a Buy rating on Amgen, with a price target of $380.00. The company’s shares closed yesterday at $300.08. Elevate Your Inv ...